Alembic Pharmaceuticals Limited (APLLTD)

Loading page…

Alembic Pharmaceuticals Limited (APLLTD) · mywealthgrid

About

Alembic Pharmaceuticals Limited is a mid-cap pharmaceutical company (market cap ₹16,342 crore) in the healthcare sector. It generates quarterly revenues of ₹1.6–₹2.1 crore with operating margins of 15–18% and net profit ranging ₹114–₹243 crore, representing an established yet operationally variable business.

Founded: 1907
Face value: ₹2

Market cap

₹16,028 Cr

P/E

23.2×

P/B

2.8×

Dividend yield

1.5%

ROE

12.3%

ROCE

14.8%

Debt / equity

0.24

OPM

15.2%

EPS (TTM)

₹35.1

Book value

₹288.7

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Net profit swings (₹114–₹243 crore) significantly exceed revenue variation (₹1.6–₹2.1 crore) — verify causes such as one-off gains, cost spikes, or tax timing
EPS volatility (₹5.82–₹12.37 across recent quarters) undercuts earnings predictability despite steady revenue — check capital structure changes, extraordinary items, and minority impacts
Negative 1-year return (–12.53%) combined with elevated PE ratio (23.7) signals market skepticism — verify whether sector-wide headwinds or company-specific factors
Pharmaceutical sector exposure to generic pricing pressure, API cost trends, and regulatory changes — verify geographic concentration, therapeutic mix, and compliance track record

Generated analysis · source review pending

Growth drivers

Operating margin reached 18.51% in Jun 2026 versus 15.23% average — if sustained, margin expansion drives EPS accretion without revenue growth
Low debt-to-equity (0.24) enables financial flexibility for capex, product development, or acquisitions — verify capital allocation strategy and investment pipeline
Mar 2026 achieved ₹12.37 EPS on quarterly revenue of ₹1,718.74 crore, among highest EPS despite below-average revenue — verify if this operational efficiency is repeatable across cycles

Generated analysis · source review pending

2,528 historical price candles were omitted because the exchange source has not been verified.

₹815.3-5.4%1Y

Quick read

rule-based

Pros

+Dividend payout of 34.2% of profit
+High promoter holding of 69.9% with no pledge

Cons

−Profit declined 10.7% a year over the last 5 years
−Modest revenue growth of 6.4% a year over the last 5 years

Research score

Structured signal from quality, growth, valuation and momentum.

60/100

Business quality: 48
Growth: 67
Valuation: 64

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	3,131	3,935	4,606	5,393	5,306	5,653	6,229	6,672	7,345
COGS	886	993	1,039	1,257	1,446	1,709	1,715	1,793	1,984
Gross profit	2,245	2,942	3,566	4,136	3,859	3,944	4,514	4,879	5,360
	1,610	2,078	2,343	2,546	2,980	3,266	3,581	3,870	4,242
	635	864	1,223	1,589	879	677	932	1,009	1,119
OPM %	20.3%	22%	26.6%	29.5%	16.6%	12%	15%	15.1%	15.2%
Depreciation	105	115	157	183	287	275	273	279	319
Interest	3	18	27	16	18	50	56	79	94
	7	9	-39	10	50	3	28	55	-13
Profit before tax	533	740	1,000	1,400	625	355	632	707	694
Tax	120	157	199	253	104	13	16	125	23
Tax %	22.6%	21.2%	19.9%	18.1%	16.7%	3.6%	2.5%	17.7%	3.3%
	413	583	801	1,147	521	342	616	582	671
PAT margin %	13.2%	14.8%	17.4%	21.3%	9.8%	6.1%	9.9%	8.7%	9.1%
EPS (₹)	21.9	31	44	60.8	27.8	17.4	31.3	29.7	34.3
EPS adjusted (₹)	21.9	-0.1	42.2	59.9	27.8	17.4	31.3	29.7	34.1
	18.3%	27.4%	15.9%	23%	0%	103.4%	35.1%	37.1%	35%
Annual report	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	38	38	38	38	39	39	39	39	39	39	39
Reserves	927	1,560	2,182	2,681	—	5,028	5,198	4,331	4,779	5,152	5,636
Minority interest	0	0	0	—	—	—	—	—	—	—	—
	207	114	708	928	—	500	630	636	430	1,196	1,361
	450	717	1,013	1,131	—	1,142	1,254	1,176	1,197	1,386	1,727
Total equity & liabilities	1,621	2,429	3,941	4,778	—	6,709	7,122	6,183	6,446	7,773	8,763
	489	708	993	1,158	1,552	1,788	1,798	2,398	2,547	2,524	3,081
CWIP	83	93	911	1,341	—	1,944	2,206	601	524	837	634
Investments	0	0	0	0	—	236	118	96	93	127	141
	1,049	1,628	2,036	2,277	—	2,740	3,000	3,087	3,281	4,285	4,907
Total assets	1,621	2,429	3,941	4,778	—	6,709	7,122	6,183	6,446	7,773	8,763

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	74.8%	77.4%	76.7%	72.7%	69.8%	72.5%	73.1%	73%
EBITDA margin %	22.2%	26.6%	28.9%	16.5%	12.5%	15%	15.1%	15.2%
EBIT margin %	19.3%	23.1%	25.5%	11.1%	7.7%	10.6%	10.9%	10.9%
PAT margin %	14.8%	17.4%	21.3%	9.8%	6.1%	9.9%	8.7%	9.1%
Working capital
Receivable days	45	—	24	56	68	60	77	73
Inventory days	356	—	431	406	315	350	466	462
Payable days	237	—	194	178	145	157	179	154
NWC days	164	—	261	283	237	253	363	381
Leverage
Current ratio	1.31	—	2.07	1.67	1.78	2.12	1.69	1.75
Debt to EBITDA	1.06	—	0.32	0.72	0.9	0.46	1.19	1.22
Debt to equity	0.34	—	0.1	0.12	0.15	0.09	0.23	0.24
Interest coverage	41.7	39.4	86.4	36	8.7	12.3	9.8	9.1
Asset turnover	0.82	—	0.8	0.74	0.91	0.97	0.86	0.84
Return ratios
Return on assets %	12.2%	—	17.1%	7.3%	5.5%	9.6%	7.5%	7.7%
Return on capital employed %	23.3%	—	25.5%	11.8%	8.8%	14.4%	14.9%	14.8%
Return on equity %	21.5%	—	22.6%	9.9%	7.8%	12.8%	11.2%	11.8%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	69.61%	69.61%	69.61%	69.61%	69.61%	69.61%	69.67%	69.67%	69.74%	69.74%	69.74%	69.87%
	4.51%	4.52%	4.46%	4.32%	3.94%	4.17%	3.94%	3.96%	4.05%	4.24%	4.25%	4.18%
	14.22%	14.5%	15.38%	15.47%	16.05%	16.06%	16.43%	16.46%	16.3%	16.17%	16.18%	15.94%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	11.66%	11.37%	10.55%	10.6%	10.4%	10.16%	9.96%	9.91%	9.91%	9.85%	9.83%	10.01%
No. of shareholders	—	—	—	—	—	—	—	—	89,969	87,000	86,432	86,796

Promoter holding up 0.26 percentage points since Sep 2023.

8 disclosures

Person	Deal	Shares	Value	Holding	Filed
Nirayu Private LimitedPromoter Group	BuyMarket Purchase	10,000	₹90.35 L	35.64% → 35.65%	1 Oct 20257(2)
Nirayu Private LimitedPromoter Group	BuyMarket Purchase	5,000	₹45.09 L

12 deals · 19 Sept 2022 – 11 Oct 2022

Date	Client	Type	Venue	Side	Quantity	Price	Value
11 Oct 2022	ISHARES CORE MSCI EMERGING MARKETS ETF	Block	BSE	Buy	1,84,251	₹611.25	₹11.26 Cr
11 Oct 2022	ISHARES CORE EMERGING MARKETS MAURITIUS CO	Block	BSE	Sell	1,84,251	₹611.25	₹11.26 Cr
11 Oct 2022	ISHARES MSCI INDIA SMALL-CAP ETF	Block	BSE	Buy	25,903	₹611.25	₹1.58 Cr
11 Oct 2022	ISHARES INDIA SC MAURITIUS COMPANY	Block	BSE	Sell	25,903	₹611.25	₹1.58 Cr
3 Oct 2022	ISHARES CORE MSCI EMERGING MARKETS ETF	Block	NSE	Buy	1,78,908	₹604.65	₹10.82 Cr
3 Oct 2022	ISHARES CORE EMERGING MARKETS MAURITIUS CO	Block	NSE	Sell	1,78,908	₹604.65	₹10.82 Cr
3 Oct 2022	ISHARES MSCI INDIA SMALL-CAP ETF	Block	NSE	Buy	25,151	₹604.65	₹1.52 Cr
3 Oct 2022	ISHARES INDIA SC MAURITIUS COMPANY	Block	NSE	Sell	25,151	₹604.65	₹1.52 Cr
19 Sept 2022	ISHARES CORE EMERGING MARKETS MAURITIUS CO	Block	BSE	Sell	1,94,642	₹609.90	₹11.87 Cr
19 Sept 2022	ISHARES CORE MSCI EMERGING MARKETS ETF	Block	BSE	Buy	1,94,642	₹609.90	₹11.87 Cr

1–10 of 12

1 / 2

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. Chirayu AminChairperson
Mr. Chirayu Ramanbhai AminExecutive Director-Chairperson related to Promoter
Mr. Pranav Chirayu AminExecutive Director-MD
Mr. Shaunak Chirayu AminExecutive Director-MD
Mr. Ashok Kumar BaratNon-Executive - Independent Director
Mr. Jai Shishir DiwanjiNon-Executive - Independent Director
Mr. Manish Santoshkumar KejriwalNon-Executive - Independent Director
Mrs. Geeta Amit GoradiaNon-Executive - Independent Director
Mr. Sujit Jaysukh BhayaniNon - Executive Independent Director
Mr. Bhayani Sujit JaysukhNon-Executive - Independent Director
Mr. Raj Kumar BahetiNon-Executive - Non Independent Director

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 6 fund houses

Held by these funds

7.27%

of the company's equity

All mutual funds

8.73%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

18 schemes · 6 fund houses

		Shares
Portfolio of Kotak Small Cap Fund	Kotak Mahindra Mutual Fund	34.28 L	286.18	1.45%	1.744%	-0
Healthcare FundNEW	ICICI Prudential Mutual Fund	20.77 L	173.45	2.48%	1.057%	—
Small Cap Fund	DSP Mutual Fund	15 L	125.24	0.58%	0.763%	-0
Small Cap Fund	Axis Mutual Fund	14.55 L	121.51	0.39%	0.74%	-0
Healthcare Fund	DSP Mutual Fund	14.43 L	120.44	3.14%	0.734%	-0
ELSS Tax Saver Fund	DSP Mutual Fund	14.35 L	119.8	0.72%	0.73%	-0
Aggressive Hybrid Fund	DSP Mutual Fund	7.99 L	66.75	0.57%	0.407%	-0
Manufacturing Fund	ICICI Prudential Mutual Fund	7.36 L	61.43	0.86%	0.374%	+3.03 L

1–8 of 18

1 / 3

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Aug 2026Transcript AI SummaryPPTREC
May 2026Transcript AI Summary PPTREC

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

26 announcementsExport CSV

29 Sept 2026, 11:32 amInsider Trading / SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 PDF

28 Sept 2026, 6:27 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

18 Sept 2026, 5:28 pmCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Analyst / Investor Meet PDF

16 Sept 2026, 6:07 pmCompany Update

Update On USFDA Inspection Conducted During 3Rd March, 2025 To 7Th March, 2025 At Bioequivalence Facility Located At Vadodara, Gujarat.

General PDF

11 Sept 2026, 11:37 amCompany Update

Intimation Regarding Successful Completion Of Unannounced USFDA Onsite Bioequivalence Inspection.

General PDF

7 Sept 2026, 8:33 pmCompany Update

Intimation Under Regulation 30 Of SEBI LODR Regulations, 2015 - Incorporation Of A Wholly Owned Subsidiary Company

General PDF

27 Aug 2026, 4:29 pmCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Analyst / Investor Meet PDF

27 Aug 2026, 4:27 pmCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Analyst / Investor Meet PDF

Date	Category	Subject	Filing
29 Sept 2026, 11:32 am	Insider Trading / SAST Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011	Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011	PDF
28 Sept 2026, 6:27 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	74.8%	77.4%	76.7%	72.7%	69.8%	72.5%	73.1%	73%
EBITDA margin %	22.2%	26.6%	28.9%	16.5%	12.5%	15%	15.1%	15.2%
EBIT margin %	19.3%	23.1%	25.5%	11.1%	7.7%	10.6%	10.9%	10.9%
PAT margin %	14.8%	17.4%	21.3%	9.8%	6.1%	9.9%	8.7%	9.1%
Working capital
Receivable days	45	—	24	56	68	60	77	73
Inventory days	356	—	431	406	315	350	466	462
Payable days	237	—	194	178	145	157	179	154
NWC days	164	—	261	283	237	253	363	381
Leverage
Current ratio	1.31	—	2.07	1.67	1.78	2.12	1.69	1.75
Debt to EBITDA	1.06	—	0.32	0.72	0.9	0.46	1.19	1.22
Debt to equity	0.34	—	0.1	0.12	0.15	0.09	0.23	0.24
Interest coverage	41.7	39.4	86.4	36	8.7	12.3	9.8	9.1
Asset turnover	0.82	—	0.8	0.74	0.91	0.97	0.86	0.84
Return ratios
Return on assets %	12.2%	—	17.1%	7.3%	5.5%	9.6%	7.5%	7.7%
Return on capital employed %	23.3%	—	25.5%	11.8%	8.8%	14.4%	14.9%	14.8%
Return on equity %	21.5%	—	22.6%	9.9%	7.8%	12.8%	11.2%	11.8%

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	161	329	312	812	449	1,463	552	724	803	88	783
	-233	-486	-884	-756	-21	-839	-372	-448	-321	-568	-506
	72	-129	503	59	155	-597	-217	-262	-438	444	-164
Net cash flow	—	—	-69	—	—	27	-37	14	45	-37	113
Free cash flow	161	-182	-437	158	-286	804	127	281	476	-476	348
CFO / Operating profit %	—	—	48.6%	93%	36.7%	94%	63.2%	102.2%	86.1%	8.7%	70%

Alembic Pharmaceuticals Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

Announcements

Not in the F&O segment

16

1

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Compounded sales growth

Compounded profit growth

Return on equity

Alembic Pharmaceuticals Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Insider dealing

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

Announcements

Not in the F&O segment

Quarterly record

Insider dealing

Bulk & block deals

Board and management

Dividends16

Board meetings1

Ratio timeline

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

16

1